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K. Cassar,1* P. Bachoo,2 I. Ford,3 M. Greaves3 and J. Brittenden11Department of Vascular Surgery, University of Aberdeen, 2Vascular Unit, Aberdeen Royal Infirmary,
Foresterhill, and 3Department of Medicine and Therapeutics, University of Aberdeen, Aberdeen, Scotland, UKObjective. The concept of clopidogrel resistance is frequently evoked in the cardiac literature. The variability of antiplatelet
response in patients with intermittent claudication has not been investigated. The aim of this study was to describe the effect
of the addition of clopidogrel to aspirin using ex vivo measures of platelet activation in patients with life-style limiting
intermittent claudication.
Design of study. Data from randomised controlled trial.
Materials. Data from 67 patients with intermittent claudication taking part in a randomised controlled trial and who
received clopidogrel in addition to aspirin was analysed.
Methods. Platelet activation was measured using whole-blood flow cytometric measurement of ADP-stimulated fibrinogen
binding at baseline and 12 h after administration of a loading dose of 300 mg clopidogrel. Patients continued to receive
75 mg clopidogrel daily for 30 days and platelet activation was again measured at day 30. Compliance with treatment was
assessed by counting returned tablets.
Results. Six patients were excluded from analysis because of incomplete compliance with treatment. Six of the sixty-one
patients (9.8%) showed no reduction in platelet activation 12 h after administration of the loading dose of clopidogrel. At
30 days these six patients still showed no response to clopidogrel. Amongst the remaining 55 patients, the mean reduction in
fibrinogen binding after clopidogrel administration was 51.5% (95% CI: 43.8–59.2). Amongst responders there was a wide
variability in reduction of fibrinogen binding in response to clopidogrel (range 8.11–97.7%). Four of these patients (6.6%)
showed a reduction of more than 95% in fibrinogen binding.
Conclusions. Patients with intermittent claudication show a wide variability in their response to clopidogrel. While a small
proportion of these patients shows no response at all, another small group appears to respond excessively to clopidogrel.
Clinical studies are required to identify whether hyper-responders are at increased risk of bleeding complications and whether
hyporesponders are at a higher risk of thrombotic events.Keywords: Platelet activation; Clopidogrel; Intermittent claudication.Introduction
Clopidogrel is an ADP-receptor inhibitor which has
been shown to be effective in the treatment of
atherothrombotic disease.1–3 There is, however,
increasing evidence that in patients with ischaemic
heart disease, the antiplatelet response in patients
receiving loading or standard doses of clopidogrel is
highly variable.4–6 Indeed despite treatment with
clopidogrel up to 10% of patients experience acute or
subacute thrombosis after implantation of a coronary
stent.4–6 As a result the concept of clopidogrel
resistance has been increasingly used in the cardiacing author. K Cassar, MD, FRCS(Gen Surg), MMEd,
scular Unit, Aberdeen Royal Infirmary, Foresterhill,
25 2ZN, Scotland, UK.
: k.cassar@abdn.ac.uk
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clopidogrel resistance means but has been used to
reflect failure of clopidogrel to achieve its antiaggre-
gatory effect. Different platelet assessments and
definitions for establishing what constitutes failure of
effect have been used. Despite this lack of consensus
there is general agreement that the antiplatelet effect of
clopidogrel is variable in patients with cardiac
disease.4–6
The variability in response may be due to a number
of mechanisms which may be classified into two
categories: extrinsic and intrinsic. Extrinsic mechan-
isms include poor or inadequate compliance with
treatment,7 and drug–drug interactions.8 Intrinsic
mechanisms include genetic polymorphisms of the
P2Y12 receptor gene9 and polymorphisms of the
CYP3As which are the hepatic enzymes responsibleEur J Vasc Endovasc Surg 32, 71–75 (2006)
doi:10.1016/j.ejvs.2006.01.013, available online at http://www.sciencedirect.com onved.
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olite.10 Increased release of ADP and up-regulation of
other platelet activation pathways may also be
involved.11
The clinical relevance of clopidogrel resistance has
been demonstrated in a study that showed that in
patients undergoing percutaneous coronary interven-
tion, a poor antiplatelet response to clopidogrel
correlated with an increased risk of recurrent athero-
thrombotic events.12
The variability in antiplatelet response to clopido-
grel in patients with peripheral arterial occlusive
disease has not been investigated. Patients with
peripheral arterial occlusive disease are at significantly
increased risk of cardiovascular events.13 Further-
more, patients undergoing endovascular or bypass
surgery for their condition are at risk both for
thrombotic events as well as bleeding complications.
Variability in antiplatelet response to clopidogrel in
this group of patients, therefore, has significant clinical
implications.Materials and Methods
Data from patients randomised to the clopidogrel arm
of a previously reported randomised controlled trial14
investigating the antiplatelet effects of aspirin–clopi-
dogrel combination versus aspirin alone after lower
limb angioplasty was analysed. All patients between
the ages of 18 and 80 years referred to the Vascular
Unit, Aberdeen Royal Infirmary with lifestyle limiting
claudication of the legs, and duplex imaging that
showed arterial stenosis or occlusion in either the
aortoiliac or femoropopliteal segments suitable for
angioplasty were considered for participation in the
study. Approval for the study was granted by the local
ethics committee and permission for Sanofi-Synthe-
labo, Guildford, UK to supply clopidogrel for this
study was obtained from the Medicines Control
Agency. The results of this randomised controlled
trial showed that combination aspirin–clopidogrel has
a greater antiplatelet effect compared to aspirin alone
in patients with intermittent claudication.Interventions
Patients were randomized to receive either 75 mg
clopidogrel in addition to 75 mg aspirin, daily for
30 days with a loading dose of 300 mg clopidogrel or
75 mg aspirin and placebo daily with a ‘loading dose’
of placebo. All patients had been taking 75 mg aspirin
for at least 1 month before recruitment into the trial.Eur J Vasc Endovasc Surg Vol 32, July 2006Data from patients in the clopidogrel arm of the trial
are included in this study.
Blood samples were taken at baseline, 12 h after
administration of 300 mg clopidogrel and on day 30.
Platelet function was assessed using whole blood flow
cytometry. Platelet responsiveness to stimulation was
measured using adenosine-5 0-diphosphate (ADP)-
stimulated platelets binding fibrinogen at each time-
point. The percentage reduction in ADP-stimulated
platelet fibrinogen binding at 12 h after administration
of clopidogrel and at day 30 were measured.
Blood samples were collected using a 21-G needle
inserted into an antecubital vein with the cuff applied
to the upper arm. The cuff was removed once the first
trickle of blood appeared into the 1:10 3.2% sodium
citrate Vacutainers (Becton Dickinson, Oxford, UK).
Fifty microlitres of blood was transferred immediately
using a micropipette and diluted in 450 ml buffer
containing 10 mmol/l HEPES, 145 mmol/l sodium
chloride, 5 mmol/l potassium chloride and 1 mmol/l
magnesium sulphate, pH 7.4.Whole blood flow cytometry
Platelet fibrinogen binding was measured by flow
cytometry of diluted whole blood as described
previously.15 Ex vivo stimulation was achieved using
10 mmol ADP. The results were reported as percentage
of platelets binding fibrinogen.Compliance
The drugs were supplied by the Trials Drug Pharmacy
Department. Compliance with medication was
assessed by counting returned tablets of clopidogrel.Statistics
Data analysis was carried out using SPSS version
13.0.1, Chicago, Illinois. Wilcoxon signed ranks test
was used to analyse the difference in ADP-stimulated
fibrinogen binding at different time points.Results
One hundred and thirty-two patients with intermittent
claudication were recruited and randomized to the
study, 65 to aspirin with placebo and 67 to aspirin plus
clopidogrel. Data from the latter 67 patients have been
included in this study. Table 1 shows the demo-
graphics of the 67 patients receiving clopidogrel. Six
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Fig. 2. Variability in percentage reduction in ADP-stimulated
fibrinogen binding 12 h after 300 mg clopidogrel loading
dose.
Table 1. Baseline clinical characteristics
Sex ratio (M:F) 52:15
Mean (range) age (years) 66.1 (43–80)
Smoking (%)
Never smoked 5 (7)
Ex smokerO1 year 28 (42)
Ex smoker!1 year 11 (16)
Smoker 23 (34)
Diabetes 12 (18)
Mean (SD) serum cholesterol
(mmol/l)
4.2 (2.0)
Mean (SD) body mass index 25.5 (4.1)
Median (range) ABPI 0.65 (0.36–0.91)
ABPI, ankle brachial pressure index in worse affected leg.
Variable Responsiveness to Clopidogrel 73patients were excluded because of non- or poor
compliance with treatment. Results from 61 patients
were available for analysis.
At baseline the mean ADP-stimulated fibrinogen
binding was 69.6% (range 24–97.6%; SD 19.3%). At
12 h after 300 mg loading dose of clopidogrel the mean
ADP-stimulated fibrinogen binding was significantly
reduced to 37.6% (range 0.75–83.7%; p!0.001). After
30 days of clopidogrel the mean was still significantly
reduced at 33.9% (range 0.89–90.2%; p!0.001) (Fig. 1).
There was no significant difference in ADP-stimulated
fibrinogen binding between the 12 h and day 30
samples (pZ0.434). In the placebo group, the mean
ADP-stimulated fibrinogen binding was 70.1, 69.5 and
69.9% at baseline, 12 h post-loading dose and day 30,
respectively, showing no change from baseline levels.
Six patients out of 61 who were compliant with their
medication (9.8%) showed no reduction in ADP-
stimulated fibrinogen binding 12 h after adminis-
tration of the loading dose. Of the remaining 55
patients the mean percentage reduction in ADP-
stimulated fibrinogen binding at 12 h was 51.5%.Day 3012 hoursBaseline
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Fig. 1. ADP-stimulated platelet fibrinogen binding (%) at
baseline, 12 h after loading dose and at day 30.There was, however, considerable variability in
responsiveness to clopidogrel amongst those patients
who showed any response with a range of between
8.11 and 97.7% reduction in ADP-stimulated fibrino-
gen binding after loading dose (Fig. 2). Four patients
(6.6%) showed a very marked reduction of over 95% in
platelet responsiveness to stimulation after adminis-
tration of the loading dose.
At day 30 all six patients who showed no response
at 12 h, still had shown no significant reduction in
ADP-stimulated fibrinogen binding.Discussion
This study demonstrates a marked variability in
response to the antiplatelet agent clopidogrel in
patients with peripheral arterial occlusive disease
receiving aspirin.
It identifies a small but not insignificant proportion
of this group of patients who fail to show any response
to clopidogrel. Although we used tablet counting to
assess compliance, non-compliance may possibly still
have contributed to this. A further small proportion of
patients demonstrate a very dramatic reduction in
platelet responsiveness to stimulation even after a
single dose of 300 mg of clopidogrel. This appears to
be consistent with the findings in patients undergoing
coronary stenting in whom clopidogrel ‘non-respon-
siveness’ has been reported in between 5 and 56% of
patients.4–6 Serebruany et al.16 recently reported that
the proportion of ‘hyporesponders’ and ‘hyper-
responders’ to clopidogrel amongst a mixed group of
patients with heart failure, stroke, coronary stenting
and volunteers was 4.2 and 4.8%, respectively.Eur J Vasc Endovasc Surg Vol 32, July 2006
K. Cassar et al.74The response of subjects in this study followed a
normal bell-shaped distribution with a wide range.
Clopidogrel was initially shown to be more effective
than aspirin in reducing the combined risk of
ischaemic stroke, myocardial infarction or vascular
death in patients with atherosclerotic disease in the
CAPRIE study.1 In this study, patients with peripheral
arterial disease were the only group that showed a
significant relative risk reduction (23.8%; pZ0.0028)
when treated with clopidogrel compared to aspirin
alone. Patients with a history of stroke or myocardial
infarction showed no significant relative risk reduction
(7.3%; pZ0.26; and K3.7%; pZ0.66, respectively).
These findings suggested that patients with peripheral
arterial occlusive disease may respond better to
clopidogrel than patients with cardiac or cerebrovas-
cular disease although the study was not powered for
sub-group analysis. The findings of our study show
that at least in ex vivo studies, the proportion of
‘hyporesponders’ and ‘hyper-responders’ to clopido-
grel amongst patients with peripheral arterial occlu-
sive disease is similar to that reported in patients with
cardiac disease.
Clopidogrel in combination with aspirin has been
shown to decrease the occurrence of death, myocar-
dial infarction and stroke by 20–27% compared with
the use of aspirin alone.2,3 Patients with peripheral
arterial occlusive disease are at the same risk of
sustaining a myocardial infarction as patients with
established coronary heart disease.17 The risks are
higher around the time of endovascular or surgical
interventions to treat these patients. Because of
concerns regarding bleeding complications as a result
of clopidogrel use, manufacturer’s recommendations
are that clopidogrel should be discontinued 7 days
prior to surgery. The Peripheral Arterial Diseases
Antiplatelet Consensus Group recommended in their
consensus statement that in patients with peripheral
arterial disease undergoing even angioplasty or
stenting of the peripheral arteries consideration
should be made to stopping clopidogrel 5 days
prior to the procedure.18 The same recommendation
was made for patients undergoing elective peripheral
bypass surgery. The risk of cardiovascular events in
this group of patients is generally high and is
increased in the peri-operative and peri-procedural
period. Withdrawing antiplatelet treatment before
high-risk interventions inevitably compounds the
risk. This study shows that there is a very wide
variability in antiplatelet response to clopidogrel. If
these results correspond to clinical outcomes in
patients with peripheral arterial disease, as has been
suggested in patients with coronary stenting12 it is
likely that a significant proportion of patientsEur J Vasc Endovasc Surg Vol 32, July 2006currently treated with clopidogrel are not getting
the expected benefit from antiplatelet treatment.
Furthermore, while the risk of bleeding complications
may be particularly high in ‘hyper-responders’, this
may not be the case in patients with a moderate or
low response. As a result of concerns regarding
bleeding, patients at high risk of cardiovascular
events will continue to be exposed to an even higher
risk through discontinuation of clopidogrel before
endovascular or surgical intervention. Clinical studies
are required to identify whether there is a correlation
between response to antiplatelet treatment and
clinical outcomes.
There is an urgent need to identify a quick and
reliable way of assessing an individual patient’s
response to antiplatelet treatment and to correlate
treatment response to clinical outcomes. Aleil et al.19
have recently shown that flow cytometric analysis of
VASP phosphorylation is a suitable test to evaluate the
efficacy of clopidogrel treatment. Although this is
encouraging, flow cytometry is an expensive and
labour-intensive tool that is only available for research
purposes and its applicability in the clinical setting
would be limited. A point-of-care system to assess
response to antiplatelet treatment is required to ensure
that all patients receive appropriate benefit from
targeted antiplatelet treatment without being exposed
to a significant risk of bleeding particularly around the
time of intervention.References
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